Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures

被引：14

作者：

Thoueille, Paul ^{[1
,2
]}

Cavassini, Matthias ^{[2
,3
]}

Guidi, Monia ^{[1
,2
,4
,5
]}

Buclin, Thierry ^{[1
,2
]}

Girardin, Francois R. ^{[1
,2
]}

Decosterd, Laurent A. ^{[1
,2
]}

Marzolini, Catia ^{[1
,6
,7
,8
,9
]}

机构：

[1] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Lausanne, Switzerland

[2] Univ Lausanne, Lausanne, Switzerland

[3] Lausanne Univ Hosp, Dept Med, Serv Infect Dis, Lausanne, Switzerland

[4] Lausanne Univ Hosp, Ctr Res & Innovat Clin Pharmaceut Sci, Lausanne, Switzerland

[5] Univ Lausanne, Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland

[6] Univ Basel, Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland

[7] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, England

[8] Lausanne Univ Hosp, Dept Lab Med & Pathol, Serv & Lab Clin Pharmacol, Rue Bugnon 17, Lausanne, Switzerland

[9] Univ Lausanne, Rue Bugnon 17, Lausanne, Switzerland

来源：

OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 02期

基金：

瑞士国家科学基金会;

关键词：

cabotegravir; guidance; long-acting; rilpivirine; TDM; ADULTS;

D O I：

10.1093/ofid/ofae023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The interpretation of long-acting cabotegravir and rilpivirine concentrations is complicated by the lack of consensus on the threshold to consider. Building on real-world therapeutic drug monitoring data and documented virologic failures, this article provides a reappraisal of the existing thresholds and guidance for the interpretation of cabotegravir and rilpivirine concentrations. There is no established threshold for the interpretation of long-acting cabotegravir/rilpivirine concentrations. Building on real-world TDM data and documented virologic failures, this article provides a reappraisal of the existing thresholds, and guidance for the interpretation of cabotegravir and rilpivirine concentrations.

引用

页数：4

共 13 条

[1] Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals [J].

Aouri, Manel ;

Barcelo, Catalina ;

Guidi, Monia ;

Rotger, Margalida ;

Cavassini, Matthias ;

Hizrel, Cedric ;

Buclin, Thierry ;

Decosterd, Laurent A. ;

Csajka, Chantal .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)

[2]

Bailon L., 2023, 19 EUROPEAN AIDS C

[3]

Ehret R., 2023, 19 EUROPEAN AIDS C

[4]

Han K., 2021, HIV RES PREVENTION H

[5] Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial [J].

Landovitz, Raphael J. ;

Li, Sue ;

Eron Jr, Joseph J. ;

Grinsztejn, Beatriz ;

Dawood, Halima ;

Liu, Albert Y. ;

Magnus, Manya ;

Hosseinipour, Mina C. ;

Panchia, Ravindre ;

Cottle, Leslie ;

Chau, Gordon ;

Richardson, Paul ;

Marzinke, Mark A. ;

Eshleman, Susan H. ;

Kofron, Ryan ;

Adeyeye, Adeola ;

Burns, David ;

Rinehart, Alex R. ;

Margolis, David ;

Cohen, Myron S. ;

McCauley, Marybeth ;

Hendrix, Craig W. .

LANCET HIV, 2020, 7 (07) :E472-E481

[6] Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial [J].

Margolis, David A. ;

Brinson, Cynthia C. ;

Smith, Graham Hr ;

de Vente, Jerome ;

Hagins, Debbie P. ;

Eran, Joseph J. ;

Griffith, Sandy K. ;

St Clair, Marty H. ;

Stevens, Marita C. ;

Williams, Peter E. ;

Ford, Susan L. ;

Stand, Britt S. ;

Bomar, Melinda M. ;

Hudson, Krischan J. ;

Smith, Kimberly Y. ;

Spreen, William R. .

LANCET INFECTIOUS DISEASES, 2015, 15 (10) :1145-1155

[7] Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir plus Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure [J].

Orkin, Chloe ;

Schapiro, Jonathan M. ;

Perno, Carlo F. ;

Kuritzkes, Daniel R. ;

Patel, Parul ;

DeMoor, Rebecca ;

Dorey, David ;

Wang, Yongwei ;

Han, Kelong ;

Van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan L. ;

Latham, Christine L. ;

St. Clair, Marty ;

Polli, Joseph W. ;

Vanveggel, Simon ;

Vandermeulen, Kati ;

D'Amico, Ronald ;

Garges, Harmony P. ;

Zolopa, Andrew ;

Spreen, William R. ;

van Wyk, Jean ;

Cutrell, Amy G. .

CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) :1423-1431

[8] Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study [J].

Orkin, Chloe ;

Morell, Enrique Bernal ;

Tan, Darrell H. S. ;

Katner, Harold ;

Stellbrink, Hans-Juergen ;

Belonosova, Elena ;

DeMoor, Rebecca ;

Griffith, Sandy ;

Thiagarajah, Shanker ;

Van Solingen-Ristea, Rodica ;

Ford, Susan L. ;

Crauwels, Herta ;

Patel, Parul ;

Cutrell, Amy ;

Smith, Kimberly Y. ;

Vandermeulen, Kati ;

Birmingham, Eileen ;

St Clair, Marty ;

Spreen, William R. ;

D'Amico, Ronald .

LANCET HIV, 2021, 8 (11) :E668-E678

[9] Long-acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 (HIV-1) Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-label, Phase 3b, Noninferiority Study [J].

Overton, Edgar T. ;

Richmond, Gary ;

Rizzardini, Giuliano ;

Thalme, Anders ;

Girard, Pierre-Marie ;

Wong, Alexander ;

Porteiro, Norma ;

Swindells, Susan ;

Reynes, Jacques ;

Noe, Sebastian ;

Harrington, Conn ;

Espanol, Carlos Martin ;

Acuipil, Carolina ;

Aksar, Asma ;

Wang, Yuanyuan ;

Ford, Susan L. ;

Crauwels, Herta ;

van Eygen, Veerle ;

Van Solingen-Ristea, Rodica ;

Latham, Christine L. ;

Thiagarajah, Shanker ;

D'Amico, Ronald ;

Smith, Kimberly Y. ;

Vandermeulen, Kati ;

Spreen, William R. .

CLINICAL INFECTIOUS DISEASES, 2023, 76 (09) :1646-1654

[10]

Rubenstein E., 2023, 19 EUROPEAN AIDS C

← 1 2 →